Glucocorticoids stimulate inflammatory 5-lipoxygenase gene expression and protein translocation in the brain

被引:60
作者
Uz, T [1 ]
Dwivedi, Y [1 ]
Savani, PD [1 ]
Impagnatiello, F [1 ]
Pandey, G [1 ]
Manev, H [1 ]
机构
[1] Univ Illinois, Coll Med, Dept Psychiat, Inst Psychiat, Chicago, IL 60612 USA
关键词
5-lipoxygenase; FLAP (5-lipoxygenase-activating protein); corticosterone; dexamethasone; hippocampus; cerebellum;
D O I
10.1046/j.1471-4159.1999.0730693.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In the brain, the expression of 5-lipoxygenase (5-LO), the enzyme responsible for the synthesis of inflammatory leukotrienes, increases during aging. Antiinflammatory drugs are currently being evaluated for the treatment of aging-associated neurodegenerative diseases such as Alzheimer's disease. Although generally considered antiinflammatory, glucocorticoids, whose production also increases during aging, are not particularly effective in this disease. In human monocytes, 5-LO mRNA content increases on exposure to the synthetic glucocorticoid dexamethasone, which prompted us to hypothesize that glucocorticoids might increase 5-LO expression in the brain as well, We treated rats for 10 days either with corticosterone (implanted subcutaneously) or with dexamethasone (injected daily); they were killed on day 10 after pellet implantation or 24 h after the 10th dexamethasone injection. We found increased levels of 5-LO mRNA and protein in hippocampus and cerebellum of glucocorticoid-treated rats; 5-LO-activating protein (FLAP) mRNA content was not affected. Using western immunobloting, we also observed the concurrent translocation of 5-LO protein from cytosol to membrane, an indication of its activation. Thus, glucocorticoid-mediated up-regulation of the neuronal 5-LO pathway may contribute to rendering an aging brain vulnerable to degeneration.
引用
收藏
页码:693 / 699
页数:7
相关论文
共 29 条
[1]   Protective effect of the 5-lipoxygenase inhibitor AA-861 on cerebral edema after transient ischemia [J].
Baskaya, MK ;
Hu, YG ;
Donaldson, D ;
Maley, M ;
Rao, AM ;
Prasad, MR ;
Dempsey, RJ .
JOURNAL OF NEUROSURGERY, 1996, 85 (01) :112-116
[2]  
Breitner JCS, 1996, NEUROBIOL AGING, V17, P789
[3]   Opioids, NSAIDs and 5-lipoxygenase inhibitors act synergistically in brain via arachidonic acid metabolism [J].
Christie, MJ ;
Vaughan, CW ;
Ingram, SL .
INFLAMMATION RESEARCH, 1999, 48 (01) :1-4
[4]   REQUIREMENT OF A 5-LIPOXYGENASE-ACTIVATING PROTEIN FOR LEUKOTRIENE SYNTHESIS [J].
DIXON, RAF ;
DIEHL, RE ;
OPAS, E ;
RANDS, E ;
VICKERS, PJ ;
EVANS, JF ;
GILLARD, JW ;
MILLER, DK .
NATURE, 1990, 343 (6255) :282-284
[5]   Glucocorticoid and mineralocorticoid receptors: Biology and clinical relevance [J].
Funder, JW .
ANNUAL REVIEW OF MEDICINE, 1997, 48 :231-240
[6]   CHARACTERIZATION OF THE HUMAN 5-LIPOXYGENASE GENE PROMOTER [J].
HOSHIKO, S ;
RADMARK, O ;
SAMUELSSON, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (23) :9073-9077
[7]  
Lammers CH, 1996, J NEUROCHEM, V66, P147
[8]   HIPPOCAMPAL AGING AND ADRENOCORTICOIDS - QUANTITATIVE CORRELATIONS [J].
LANDFIELD, PW ;
WAYMIRE, JC ;
LYNCH, G .
SCIENCE, 1978, 202 (4372) :1098-1102
[9]   Tyrosine kinase activity modulates catalysis and translocation of cellular 5-lipoxygenase [J].
Lepley, RA ;
Muskardin, DT ;
Fitzpatrick, FA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (11) :6179-6184
[10]  
LOWRY OH, 1951, J BIOL CHEM, V193, P265